Journal of Personalized Medicine (Apr 2023)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases

  • Mariangela Manfredi,
  • Lieve Van Hoovels,
  • Maurizio Benucci,
  • Riccardo De Luca,
  • Carmela Coccia,
  • Pamela Bernardini,
  • Edda Russo,
  • Amedeo Amedei,
  • Serena Guiducci,
  • Valentina Grossi,
  • Xavier Bossuyt,
  • Carlo Perricone,
  • Maria Infantino

DOI
https://doi.org/10.3390/jpm13040688
Journal volume & issue
Vol. 13, no. 4
p. 688

Abstract

Read online

The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells. Mirroring local inflammation and immune activation, suPAR has gained interest as a potential prognostic biomarker in several inflammatory diseases. Indeed, in many diseases, including cancer, diabetes, cardiovascular diseases, kidney diseases, and inflammatory disorders, higher suPAR concentrations have been associated with disease severity, disease relapse, and mortality. Our review describes and discusses the supporting literature concerning the promising role of suPAR as a biomarker in different autoimmune rheumatic and non-rheumatic diseases.

Keywords